Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 14Burkitt Lymphoma 10Neoplasms 7Lymphoma, Follicular 6Hodgkin Disease 6Triple Negative Breast Neoplasms 5Sarcoma 5Ovarian Neoplasms 5Lymphoma, Non-Hodgkin 5Lymphoma 5Endometrial Neoplasms 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, B-Cell 4Breast Neoplasms 4Wilms Tumor 3Sarcoma, Ewing 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Osteosarcoma 3Lymphoma, Mantle-Cell 3Liposarcoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Fallopian Tube Neoplasms 3Plasmablastic Lymphoma 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoproliferative Disorders 2Lymphoma, B-Cell, Marginal Zone 2Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2

Interventions

prednylidene 1etoposide phosphate 1deltacortene 1Vincristine 1Vinblastine 1Specimen Handling 1Procarbazine 1Prednisone 1Prednisolone 1Nivolumab 1Methylprednisolone 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Etoposide 1Doxorubicin 1Dacarbazine 1Cyclophosphamide 1Brentuximab Vedotin 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 × Doxorubicin × 30 days × Clear all
NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡